Researchers at China Pharmaceutical University have developed a multisite bridging-mediated lateral flow immunoassay (mbLFIA) that detects mosquito-borne viruses like Chikungunya (CHIKV) with high sensitivity without the need for specialized laboratory equipment. According to a study published in Targetome on April 30, 2026, the method achieves a visual detection limit of 2 pmol·L−1, offering a portable diagnostic tool for resource-limited settings.
Advancing Diagnostic Sensitivity in Field Settings
Conventional viral detection often relies on reverse transcription polymerase chain reaction (RT-PCR) or other isothermal amplification methods that require thermal cycling, fluorescence readers, or complex enzyme systems. While existing lateral flow assays are portable, they often lack the sensitivity required for early-stage infection detection. The new mbLFIA platform addresses this by utilizing a two-round catalytic hairpin assembly (CHA) system.
The research team, led by Yanmin Ju, designed four hairpin probes (H1, H2, H3, and H4). When CHIKV target RNA is present, it initiates hybridization cycles that produce H3H4 complexes. These complexes are engineered with multiple binding sites, which significantly improve the ability to bridge Au@Pt nanoparticle probes to the test line. According to the study, this multisite structure produced signals nearly 10 times stronger than traditional limited-site designs.
Pro Tip: The use of Au@Pt nanoparticles serves a dual purpose: they function as both a visual marker and a catalyst. By catalyzing the oxidation of 3-amino-9-ethylcarbazole (AEC), the nanoparticles create an insoluble brown-red precipitate, which further amplifies the test signal.
Performance and Clinical Validation
To evaluate the platform’s reliability, researchers tested it against a variety of mosquito-borne viruses, including Dengue (DENV), Zika (ZIKV), West Nile (WNV), Yellow fever (YFV), Japanese encephalitis (JEV), and Getah (GETV). The mbLFIA showed high specificity for CHIKV, with signal intensities significantly lower for the other tested viruses.
Clinical accuracy was verified using 36 suspected CHIKV mouse serum samples. The mbLFIA results demonstrated 100% concordance with RT-PCR, correctly identifying all 16 positive and 20 negative samples. Additionally, the assay maintained recovery rates between 80% and 120% when tested in complex biological matrices such as spiked serum, saliva, and urine, suggesting strong practical utility for clinical diagnostics.
Future Trends in Point-of-Care Testing
The rise in global travel and climate-driven vector expansion has increased the urgency for rapid, on-site diagnostic capabilities. The mbLFIA strategy represents a shift toward “instrument-free” diagnostics that maintain the precision of laboratory-grade nucleic acid testing. By moving away from energy-intensive thermal cycling, this platform is positioned for deployment in ports, field stations, and remote regions where electricity and sophisticated infrastructure are often unavailable.
Did you know? The researchers confirmed the composition of their Au@Pt nanoparticles using advanced imaging and spectroscopy techniques, including transmission electron microscopy (TEM) and X-ray photoelectron spectroscopy (XPS), ensuring the stability of the nano-catalysts used in the assay.
Frequently Asked Questions
How does the mbLFIA differ from a standard rapid test?
Unlike standard lateral flow tests that often rely on antibody-antigen binding, the mbLFIA detects intrinsic viral gene sequences through nucleic acid amplification. It uses a catalytic hairpin assembly to amplify the signal, making it significantly more sensitive.
Does this test require electricity or refrigeration?
No. The platform is designed to be enzyme-free and does not require thermal cycling or complex laboratory instruments, making it suitable for field deployment in resource-limited areas.
Can this method detect viruses other than Chikungunya?
While the study used CHIKV as a model target, the researchers suggest the platform is adaptable for other nucleic acid testing applications, potentially supporting broader infectious disease surveillance.
Are you interested in the latest developments in diagnostic technology? Subscribe to our newsletter for updates on how new research is changing the landscape of global health and infectious disease control.
Related reading